These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Lipid nanoparticles for short interfering RNA delivery. Leung AK; Tam YY; Cullis PR Adv Genet; 2014; 88():71-110. PubMed ID: 25409604 [TBL] [Abstract][Full Text] [Related]
24. Lipid-based nanocarriers for delivery of small interfering RNA for therapeutic use. Parashar D; Rajendran V; Shukla R; Sistla R Eur J Pharm Sci; 2020 Jan; 142():105159. PubMed ID: 31747618 [TBL] [Abstract][Full Text] [Related]
25. Cationic lipids and polymers mediated vectors for delivery of siRNA. Zhang S; Zhao B; Jiang H; Wang B; Ma B J Control Release; 2007 Oct; 123(1):1-10. PubMed ID: 17716771 [TBL] [Abstract][Full Text] [Related]
26. Efficient nanocarriers of siRNA therapeutics for cancer treatment. Subhan MA; Torchilin VP Transl Res; 2019 Dec; 214():62-91. PubMed ID: 31369717 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers. Scholz C; Wagner E J Control Release; 2012 Jul; 161(2):554-65. PubMed ID: 22123560 [TBL] [Abstract][Full Text] [Related]
28. Preparation and characterization of polymeric nanoparticles for siRNA delivery to down-regulate the expressions of exogenous and endogenous target genes. Huang W; Lv M; Gao ZG; Jin MJ; Xu YJ; Yu XD; Jin ZH; Yin XZ Pharmazie; 2012 Aug; 67(8):676-80. PubMed ID: 22957431 [TBL] [Abstract][Full Text] [Related]
29. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Bartlett DW; Davis ME Biotechnol Bioeng; 2008 Mar; 99(4):975-85. PubMed ID: 17929316 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of copolymers of N-isopropylacrylamide and 2-dimethyl(aminoethyl)methacrylate in nonviral and adenoviral vectors for gene delivery to nasopharyngeal carcinoma. Moselhy J; Sarkar S; Chia MC; Mocanu JD; Taulier N; Liu FF; Wu XY Int J Nanomedicine; 2007; 2(3):461-78. PubMed ID: 18019844 [TBL] [Abstract][Full Text] [Related]
31. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy. Ku SH; Kim K; Choi K; Kim SH; Kwon IC Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795 [TBL] [Abstract][Full Text] [Related]
32. Polymeric siRNA gene delivery - transfection efficiency versus cytotoxicity. Kargaard A; Sluijter JPG; Klumperman B J Control Release; 2019 Dec; 316():263-291. PubMed ID: 31689462 [TBL] [Abstract][Full Text] [Related]
34. Lipid-based nanoparticles in the systemic delivery of siRNA. Lin Q; Chen J; Zhang Z; Zheng G Nanomedicine (Lond); 2014 Jan; 9(1):105-20. PubMed ID: 24354813 [TBL] [Abstract][Full Text] [Related]
35. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer. Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393 [TBL] [Abstract][Full Text] [Related]
36. Polymeric Biomaterial and Lipid Based Nanoparticles for Oral Drug Delivery. Dilnawaz F Curr Med Chem; 2017; 24(22):2423-2438. PubMed ID: 27804879 [TBL] [Abstract][Full Text] [Related]
38. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Fattal E; Bochot A Int J Pharm; 2008 Dec; 364(2):237-48. PubMed ID: 18619528 [TBL] [Abstract][Full Text] [Related]
39. Development of plasmid-lipid complexes for direct intratumoral injection. Kotipatruni RP; Nagaraju GP Methods Mol Biol; 2014; 1139():467-76. PubMed ID: 24619700 [TBL] [Abstract][Full Text] [Related]
40. Oral delivery of siRNA lipid nanoparticles: Fate in the GI tract. Ball RL; Bajaj P; Whitehead KA Sci Rep; 2018 Feb; 8(1):2178. PubMed ID: 29391566 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]